• Strategic Drug Development
  • Program Review and Gap Analysis
  • Strategic Regulatory Assessment and Planning
  • Development of Target Product Profiles (TTP)
  • Pre-clinical Consulting
  • Chemistry, Manufacturing Control (CMC) Review and Management
  • Optimization of Clinical Trial Protocols and Study Design
  • Coordination of Scientific Advisory Boards
  • Review of Candidate Products and Due Diligence
• Regulatory Science/Submissions
  • Investigational New Drug Applications (IND)
  • Clinical Trial Authorizations/Exemptions (CTA/CTX)
  • Orphan Drug Applications (ODA)
  • New Drug Applications (NDA)
  • Marketing Authorization Applications (MAA)
  • Abbreviated New Drug Applications (ANDA)
  • Biologics License Applications (BLA)
  • Pre-market Approvals (PMA/510K)
  • 505(b)2
  • Fast Track Applications
  • Post Market Obligations / Regulatory Review of Promotional Material
  • Preparation for Meetings with Regulatory Authorities
  • Interaction and Negotiation with Regulatory Authorities
  • Due Diligence
• Clinical Trial Services
  • Strategic Clinical Development
  • Project Management
  • Clinical Monitoring
  • Data Management
  • Biostatistics
  • Medical Writing
  • Pharmacokinetics

Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca.

CARLSBAD, Calif., July 21 /PRNewswire/

Abingdon Life Sciences announces the formal opening of its offices in Carlsbad, California. The offices, located at 5963 La Place Court, Suite 107, are in the Carlsbad Airport Business Park adjacent to Palomar Airport. Abingdon Life Sciences, Inc. is a first-in-class Drug, Device, Diagnostic Development Management Organization (DDMO), focused on providing drug and device companies with superior services based on an integrated strategic development model. An integrated development model focuses on the Target Product Profile (TPP) concept, and allows a platform to be assessed by key areas of opportunity and risk from both scientific and business aspects.

Abingdon was founded on the principle that a proactive strategic approach to development will yield better outcomes. Abingdon's philosophy is to provide clients with a focused approach to product development by building synergistic partnerships that use significant expertise to achieve the best outcome. Global core-competencies include pre-clinical, regulatory strategy and submissions, clinical development, biostatistics, report writing and post-marketing obligations. Abingdon provides services to clients with products initially filed under IND, CTX, 505(b)(2), NDA, ANDA, PMA and 510k applications. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience. Key alliances enable Abingdon to assist with cGMP services from formulation development for clinical trial supply through commercialization.

"Abingdon's approach is to reduce the noise in the development process and provide objective direction that outlines the risks and benefits of the potential development pathways. In the end, our goal is to assist our clients to streamline their development process and help make decisions that will achieve their goals. We believe this will ultimately reduce costs to our clients and speed the time to market," stated Aidan Nuttall, Ph.D., President and C.O.O., Abingdon Life Sciences, Inc.

About Abingdon Life Sciences, Inc.:

Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.

ABINGDON LIFE SCIENCES, INC. ENTERS INTO STRATEGIC ALLIANCE WITH STASON PHARMACEUTICALS, INC. TO PROVIDE REGULATORY AND CLINICAL SUPPORT

Carlsbad, CA, August 4th, 2008

Abingdon Life Sciences, Inc. has entered into an agreement with Stason Pharmaceuticals, Inc. to provide clinical and regulatory support for Stason's drug development programs. As part of the agreement, Abingdon will provide clinical and regulatory services for Stason's pipeline of potential drug candidates and devices in the areas of cancer and inflammation.

"We are extremely happy to have formalized our relationship with Stason, and believe that this represents a synergistic opportunity for both our companies to leverage our respective core competencies in drug development and manufacturing," said Richard Lebovitz, Abingdon CEO. Harry Fan, CEO of Stason added "Stason is pleased to have agreed to this strategic partnership with Abingdon. It is a mutually beneficial relationship bringing expertise in many areas to our clients, both here in the US and in our overseas markets."

About Abingdon Life Sciences, Inc.: Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.

About Stason Pharmaceuticals, Inc.: Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution. Stason also out-licenses internally developed technologies to companies worldwide. Stason is specialized in developing and processing high-potency products, including oncology drugs.

For More Information Contact:
Abingdon Contact:
Aidan Nuttall, Ph.D.
(1) 760-268-1078
anuttall@abingdoncorp.com

Stason Contact:
Diana Wood
(1) 760-929-0346
diana.wood@stasonpharma.com